PHSSR Policy Roadmaps for Acting Early on NCDs Synthesis Report 2025
Page 60 of 124 · WEF_PHSSR_Policy_Roadmaps_for_Acting_Early_on_NCDs_Synthesis_Report_2025.pdf
57 Acting early on NCDs
The Partnership for Health System Sustainability and ResilienceFigure 15: Hospital admissions for congestive heart failure, diabetes and COPD (adults per 100,000
population), 2011 and 2021
Notes: * = 2019 data, ** = 2020 data.
Source: OECD, 2023a.
Disease management programmes at scale
Disease management programmes (DMPs) represent one of the most significant innovations in
structured chronic care delivery, attempting to bridge the gaps created by system fragmentation and
address the disconnect between healthcare resource availability and health outcomes. These
programmes are systematic, population-based approaches to identifying and proactively managing
high-risk patients with specific chronic conditions through coordinated care interventions that span
the primary-secondary care interface. They typically include standardised clinical protocols, regular
monitoring schedules, patient education components, and care coordination mechanisms designed
to improve outcomes whilst reducing costs through prevention of complications and avoidable
hospitalisations.
Germany provides perhaps the most prominent large-scale example of structured chronic disease
management through its Disease Management Programmes (DMPs). Introduced in 2002 and now
covering millions of patients, DMPs offer standardised care pathways for major NCDs (e.g. diabetes,
cardiovascular disease, COPD, asthma) (Bundesamt für Soziale Sicherung, 2024; G-BA, 2025a;
Bundesministerium für Gesundheit, 2025b). Key features include systematic enrolment, regular
follow-up, patient education, and coordination across sectors. Providers receive extrabudgetary
reimbursement linked to adherence with guideline-based care, and contracts are negotiated
between sickness funds and physician associations (Bundesministerium für Gesundheit, 2025b).
Evaluations suggest that DMPs have improved process quality and intermediate outcomes, for
example better control of HbA1c among diabetes patients and reduced hospitalisations for
206167459160363287*161
262204575292391276188Congestive heart failure
OECDSpainPolandJapanItalyGermanyFranceCanada
2011 2021 (or latest available)1025712111**31172156*94
153602481754244203102Diabetes
23
12913283193159*132
245260281109257133270COPD
Ask AI what this page says about a topic: